Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection
| Autor: | Tanya Golubchik, Anthony C. Gordon, Rutger J. Ploeg, Ullrich Leuscher, Wendy Slack, Pat Tsang, Manu Shankar-Hari, David K. Menon, Paul R Mouncey, Sarah Williams, Lise J Estcourt, Sheba Ziyenge, Farah Al-Beidh, Heli Harvala, Nick A Ciccone, Peter Simmonds, David J. Roberts, Jeremy Ratcliff, Kathryn M Rowan, Abigail Lamikanra, Jennifer Rynne, Amy Evans, Dung Nguyen, Aislinn Jennings, Matthew Fish, Emma Laing, David Bonsall, Marta S Oliveira |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Critical Illness medicine.disease_cause SARS-CoV-2/immunology Immunoglobulin G Serology 03 medical and health sciences 0302 clinical medicine Immune system Intensive care Humans Immunology and Allergy Medicine Antibodies Viral/immunology 030212 general & internal medicine Seroconversion Immunoglobulin G/immunology Aged Coronavirus Serologic Tests/methods biology business.industry Viral Load/immunology Immunization Passive Middle Aged RNA Viral/immunology Antibodies Neutralizing/immunology United Kingdom 3. Good health COVID-19/immunology 030104 developmental biology Infectious Diseases Immunology biology.protein Female Spike Glycoprotein Coronavirus/immunology Antibody business Viral load |
| Zdroj: | 2021, ' Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom : Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection ', The Journal of Infectious Diseases, vol. 224, no. 4, pp. 595-605 . https://doi.org/10.1093/infdis/jiab283 |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1093/infdis/jiab283 |
| Popis: | BackgroundConvalescent plasma containing neutralizing antibody to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is under investigation for coronavirus disease 2019 (COVID-19) treatment. We report diverse virological characteristics of UK intensive care patients enrolled in the Immunoglobulin Domain of the REMAP-CAP randomized controlled trial that potentially influence treatment outcomes.MethodsSARS-CoV-2 RNA in nasopharyngeal swabs collected pretreatment was quantified by PCR. Antibody status was determined by spike-protein ELISA. B.1.1.7 was differentiated from other SARS-CoV-2 strains using allele-specific probes or restriction site polymorphism (SfcI) targeting D1118H.ResultsOf 1274 subjects, 90% were PCR positive with viral loads 118–1.7 × 1011IU/mL. Median viral loads were 40-fold higher in those IgG seronegative (n = 354; 28%) compared to seropositives (n = 939; 72%). Frequencies of B.1.1.7 increased from ConclusionsHigh viral loads in seropositive B.1.1.7-infected subjects and resistance to seroconversion indicate less effective clearance by innate and adaptive immune responses. SARS-CoV-2 strain, viral loads, and antibody status define subgroups for analysis of treatment efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|